Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naltrexone
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : JanOne
Deal Size : $30.0 million
Deal Type : Acquisition
JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC
Details : Jan123 (naltrexone) is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs.
Brand Name : JAN123
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 10, 2023
Lead Product(s) : Naltrexone
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : JanOne
Deal Size : $30.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?